An organisation representing cancer patients has challenged the government's decision to grant Novartis the exclusive marketing rights for imatinib, a drug that has emerged as a frontline treatment for chronic myeloid leukaemia. The petitioner, the Cancer Patients Aid Association, has said that exclusive marketing rights for the drug would eliminate cheaper generic versions of the drug and make the treatment unaffordable to thousands of patients in India.
Although Indian laws do not permit product patents on drugs, the Indian patents office has granted Novartis exclusive marketing rights for imatinib under the provisions available in an international trade agreement on intellectual property rights signed by India.
The company's product, Glivec, is a crystalline form of imatinib mesilate, a compound that blocks a specific protein implicated in chronic myeloid leukaemia. The drug has been approved for this cancer in the European Union and in more than 60 countries.
When Novartis introduced Glivec in India in May 2002, several Indian drug companies began to produce generic versions of the compound. But after Novartis received exclusive marketing rights last November, local manufacturers have had to stop selling the generic versions. The cost of a month's dose of Glivec is 120,000 rupees, 10 times higher than what the generic versions used to cost patients.
A spokeswoman for Novartis India said that more than 2380 patients in India currently receive the drug free under the Glivec international patient assistance programme. Also, oncologists and haematologists in India were familiar with the procedure for enrolling patients into the programme. Patients who were not insured and who had no funds to draw on were eligible for the programme.
The association has petitioned the court to direct the government to impose a price control on the drug. Experts in international trade law say that the government has the authority to fix prices despite the grant of exclusive marketing rights. Now the real question is whether the government is willing to act?
BMJ,
August 2004
DoctorNDTV is the one stop site for all your health needs providing the most credible health information,
health news and tips with expert advice on healthy living, diet plans, informative videos etc. You can get the most relevant and accurate info you need about health problems like
diabetes,
cancer,
pregnancy,
HIV and AIDS,
weight loss and many other lifestyle diseases. We have a panel of over 350 experts who help us develop content by giving their valuable inputs and bringing to us the latest in the world of healthcare.
Was this Article Helpful
Yes or
No